JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Survivin as a Potential Target for Cancer Therapy
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Survivin as a Potential Target for Cancer Therapy
Soleimanpour, Elaheh; Babaei, Esmaeil;
  PDF(new window)
 Abstract
In 1997 for the first time, survivin was described by Amborsini et al. as an anti-apoptotic protein. Subsequent studies revealed that survivin is a multifunctional protein that plays critical roles in several crucial cell processes such as apoptosis, cell cycle, chromosome movement, mitosis and cellular stress responses. Moreover, it`s overexpression in cancer cells versus normal cells is associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival. All of these features make survivin a promising target for cancer therapy. Here, we review the potential characteristics of survivin as a tumor marker.
 Keywords
Survivin;cancer;antiapoptotic protein;apoptosis;
 Language
English
 Cited by
1.
Survivin, a Promising Gene for Targeted Cancer Treatment,;;;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 8, pp.3711-3719 crossref(new window)
1.
Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis, BMC Cancer, 2016, 16, 1  crossref(new windwow)
2.
Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy, SpringerPlus, 2016, 5, 1  crossref(new windwow)
3.
XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis, BMC Cancer, 2017, 17, 1  crossref(new windwow)
4.
Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins, F1000Research, 2017, 6, 2046-1402, 587  crossref(new windwow)
 References
1.
Altieri DC (1994). Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem, 269, 3139-42.

2.
Altieri DC (2008). Survivin, cancer networks and pathwaydirected drug discovery. Nat Rev Cancer, 8, 61-70. crossref(new window)

3.
Altieri DC (2013). Targeting surviving in cancer. Cancer Letters, 332, 225-8. crossref(new window)

4.
Asanuma K, Moriai R, Yajima T, et al (2000). Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res, 91, 1204-9. crossref(new window)

5.
Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006). Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg, 41, 1431-40. crossref(new window)

6.
Babaei E, Mowla SJ, Shariat Torbaghan S, Emadi Baygi M (2006). Detection of surviving gene expression in formalinfixed paraffin-embedded tissue of human osteosarcoma: its potential usefulness in diagnosis and prognosis of bone tumors. IBJ, 10, 39-45.

7.
Barrett RM, Osborne TP, Wheatley SP (2009). Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle, 8, 278-83. crossref(new window)

8.
Caldas H, Fangusaro JR, Boue DR, Holloway MP, Altura RA (2007). Dissecting the role of endothelial survivin ${\Delta}Ex3$ in angiogenesis. Blood, 109, 1479-89. crossref(new window)

9.
Carrasco RA, Stamm NB, Marcusson E, et al (2011). Antisense inhibition of surviving expression as a cancer therapeutic. Mol Cancer Ther, 10, 221-32. crossref(new window)

10.
Carter BZ, Mak DH, Schober WD, et al (2006). Regulation of survivin expression through Bcr-Abl/MAPK cascade: Targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood, 107, 1555-63. crossref(new window)

11.
Castro-Gamero AM, Borges KS, et al (2013). Tetra-Omethyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. Invest New Drugs, 31, 858-70 crossref(new window)

12.
Cheng Q, Ling X, Haller A, et al (2012). Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol, 3, 179-97.

13.
Cheng Z, Hu L, Fu W, Zhang Q, Liao X (2007). Expression of survivin and its splice variants in gastric cancer. J Huazhong Univ Sci Technolog Med Sci, 27, 393-8. crossref(new window)

14.
Cheung CH, Sun X, Kanwar JR, et al (2010). A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF alpha therapy. Cancer Cell Int, 10.

15.
Colnaghi R, Wheatley SP (2010). Liaisons between survivin and Plk1 during cell division and cell death. J Biol Chem, 285, 22592-604. crossref(new window)

16.
Coumar M, Tsai F, Kanwar JR, Sarvagalla S, Cheung CH (2013). Treat cancers by targeting survivin: Just a dream or future reality? Cancer Treatment Reviews, 39, 802-11. crossref(new window)

17.
Croci DO, Cogno IS, Vittar NB, et al (2008). Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem, 105, 381-90. crossref(new window)

18.
Fisker N, Westergaard M, Hansen HF, Hansen JB (2007). Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids, 26, 1427-30. crossref(new window)

19.
Hansen JB, Fisker N, Westergaard M, et al (2008). SPC3042: a proapoptotic surviving inhibitor. Mol Cancer Ther, 7, 2736-45. crossref(new window)

20.
Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA (2004). Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem, 279, 40511-20 crossref(new window)

21.
Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW (2001). Effects of surviving antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst, 93, 1541-52. crossref(new window)

22.
Kanwar JR, Kamalapuram SK, Kanwar RK (2013). Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev, 33, 765-89. crossref(new window)

23.
Kyani K, Babaei E, Hosseinpour feizi MA, et al (2014). Detection of surviving $2{\alpha}$ gene expression in thyroid nodules. J Cancer Res Ther, 10, 312-6. crossref(new window)

24.
Lens SM, Vader G, Medema RH (2006). The case for survivin as mitotic regulator. Curr Opin Cell Biol, 18, 616-22. crossref(new window)

25.
Li F, Ambrosini G, Chu EY, et al (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-4. crossref(new window)

26.
Li F (2014). Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer? Am J Cancer Res, 4, 304-11.

27.
Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F (2010). Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res, 29, 8. crossref(new window)

28.
Ling X, Cao SS, QY, et al (2012). A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner shows superior antitumor activity. PLoS One, 7.

29.
Liu JL, Wang Y, Jiang J, et al (2010). Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA. Chin Med J, 123, 2901-7.

30.
Mesri M, Wall NR, Li J, Kim RW, Altieri DC (2001). Cancer gene therapy using a surviving mutant adenovirus. J Clin Invest, 108, 981-90. crossref(new window)

31.
Mirza A, McGuirk M, Hockenberry TN, et al (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21, 2613-22. crossref(new window)

32.
Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008). Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res, 14, 5000-5. crossref(new window)

33.
Mobahat M, Narendran A, Riabowol K (2014). Survivin as a preferential target for cancer therapy. Int J Mol Sci, 15, 2494-516. crossref(new window)

34.
Mohamed S, Yasufuku K, Nakajima T, et al (2009). Nuclear survivin in pN2 nonsmall cell lung cancer: Prognostic and clinical implications. Eur Respir J, 33, 127-33. crossref(new window)

35.
Na YS, Yang SJ, Kim SM, et al (2012). YM155 induces EGFR suppression in pancreatic cancer cell. PLoS ONE, 7, 38625. crossref(new window)

36.
Nakahara T, Kita A, Yamanaka K, et al (2012). Broad spectrum and potent antitumor activities of YM155, a novel smallmolecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci, 102, 614-21.

37.
Nouraee N, Mowla SJ, Ozhand A, et al (2009). Expression of Survivin and Its Spliced Variants in Bladder Tumors as a Potential Prognostic Marker. Urol J, 6, 101-8.

38.
O'Connor DS, Grossman D, Plescia J, et al (2000). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Nat Acad Sci, 97, 13103-7. crossref(new window)

39.
Olie RA, Simoes-Wust AP, Baumann B, et al (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 60, 2805-9.

40.
Ouyang L, Shi Z, Zhao S, et al (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 45, 487-98. crossref(new window)

41.
Pavlyukov MS, Antipova NV, Balashova MV, et al (2011). Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem, 286, 23296-307. crossref(new window)

42.
Pennati M, Binda M, Colella G, et al (2003). Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of surviving expression. J Invest Dermatol, 120, 648-54. crossref(new window)

43.
Plescia J, Salz W, Xia F, et al (2005). Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 7, 457-68. crossref(new window)

44.
Poomsawat S, Punyasingh J, Vejchapipat P (2014). Overexpression of survivin and caspase 3 in oral carcinogenesis. Appl Immunohistochem Mol Morphol, 22, 65-71. crossref(new window)

45.
Rodel C, Haas J, Groth A, et al (2003). Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys, 55, 1341-7. crossref(new window)

46.
Sah NK, Munshi A, Hobbs M, et al (2006). Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys, 66, 852-9. crossref(new window)

47.
Shariat SF, Casella R, Khoddami SM, et al (2004). Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol, 171, 626-30. crossref(new window)

48.
Sharma H, Sen S, Lo Muzio L, Mariggio A, Singh N (2005). Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther, 4, 720-7. crossref(new window)

49.
Shin S, Sung BJ, Cho YS, et al (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 40, 1117-23. crossref(new window)

50.
Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C (2003). Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene, 22, 4266-80. crossref(new window)

51.
Sung B-J, Cho Y-S, Kim H-J, et al (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 40, 1117-23. crossref(new window)

52.
Tamm I, Wang Y, Sausville E, et al (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res, 58, 5315-20

53.
Tran J, Master Z, Yu JL, et al (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A, 99, 4349-54. crossref(new window)

54.
Tu SP, Jiang XH, Lin MC, et al (2003). Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res, 63, 7724-32.

55.
Vandghanooni S, Eskandani M, Montazeri V, et al (2011). Survivin-delta Ex3: a novel biomarker for diagnosis of papillary thyroid carcinoma. J cancer Res Ther, 7, 325-30. crossref(new window)

56.
Yamamoto T, Manome Y, Nakamura M, Tanigawa N (2002). Downregulation of surviving expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer, 38, 2316-24. crossref(new window)

57.
Yamashita SI, Masuda Y, Kurizaki T, et al (2007). Survivin expression predicts early recurrencein early-stage breast cancer. Anticancer Res, 27, 2803-8.

58.
Yong-Gang Lv, Fang Yu, Qing Yao, Jiang-Hao Chen, Ling Wang (2010). The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis, 2, 100-10.

59.
You L, He B, Xu Z, et al (2004). InhibitionofWnt-2-mediated signaling induces programmed cell death in nonsmall- cell lung cancer cells. Oncogene, 23, 6170-74. crossref(new window)

60.
Zhang MC, Hu CP, Chen Q (2006). Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells. Zhonghua Zhong Liu Za Zhi, 28, 408-12.

61.
Ziaee SA, Moula SJ, Hosseini Moghaddam SM, Eskandar-Shiri D (2006). Diagnosis of bladder cancer by urine survivin, an inhibitor of apoptosis. Urol J, 3, 150-3.